What is ProQR Therapeutics BV (PRQR) stock price today?

ProQR Therapeutics BV (PRQR) currently trades at $1.57 per share. The stock has a market capitalization of $155.93M and a P/E ratio of —x.

Is PRQR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, ProQR Therapeutics BV has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -2.81.

What is ProQR Therapeutics BV's revenue and earnings?

ProQR Therapeutics BV has trailing twelve-month (TTM) revenue of $16.35M with profit margins of -258.00%. Earnings per share (EPS) is $-0.47.

Is ProQR Therapeutics BV financially healthy?

ProQR Therapeutics BV's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -2.81 places it in the distress.

PRQR

ProQR Therapeutics BV

NASDAQ: PRQR · HEALTHCARE · BIOTECHNOLOGY

$1.57

+1.95% today

Updated 2026-04-30

Market cap

$155.93M

P/E ratio

—

P/S ratio

9.54x

EPS (TTM)

$-0.47

Dividend yield

—

52W range

$1 – $3

Volume

0.6M

Market cap

$155.93M

P/E ratio

—

P/S ratio

9.54x

EPS (TTM)

$-0.47

Dividend yield

—

52W range

$1 – $3

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.7

Growth

6.5

Quality

2.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-2.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$8.88

+465.61%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.29x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -2.81 — distress zone

- Thin margins at -258.00%

- Negative free cash flow $-13.59M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$3.59M	$6.51M	$18.91M	$15.28M	$16.35M
Net income	$-64.42M	$-28.12M	$-27.76M	$-40.52M	$-8.84M
EPS	—	—	—	—	$-0.47
Free cash flow	$-69.22M	$20.18M	$-37.81M	$-51.69M	$-13.59M
Profit margin	-1,792.54%	-431.67%	-146.86%	-265.21%	-258.00%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PRQR	$155.93M	24	6.7	2.0	5.0	6.5	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

ProQR Therapeutics BV trades at $1.57. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -2.81, it sits in the distress. TTM revenue stands at $16.35M. with profit margins at -258.00%.

Frequently asked questions

What is ProQR Therapeutics BV's stock price?

ProQR Therapeutics BV (PRQR) trades at $1.57.

Is ProQR Therapeutics BV overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of ProQR Therapeutics BV (PRQR)?

The analyst target price is $8.88, representing +465.6% upside from the current price of $1.57.

What is ProQR Therapeutics BV's revenue?

TTM revenue is $16.35M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-2.81 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio9.54x

ROE-61.20%

Beta0.09

50D MA$1.67

200D MA$2.03

Shares out0.11B

Float0.06B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PRQR vs LLY →PRQR vs JNJ →PRQR vs ABBV →Stock screener →